Rekombinanter EGFR (Cetuximab Biosimilar) Antikörper
Kurzübersicht für Rekombinanter EGFR (Cetuximab Biosimilar) Antikörper (ABIN5668058)
Target
Antikörpertyp
Reaktivität
Wirt
Klonalität
Konjugat
Applikation
Klon
-
-
Verwendungszweck
- Anti-EGFR [C225 (Cetuximab)], Human IgG1, kappa
-
Spezifität
- Recognises human EGFR.
-
Produktmerkmale
-
Original Species of Ab: Human
Original Format of Ab: IgG1
-
Aufreinigung
- Protein A affinity purified
-
Reinheit
- > 98 % as determined by SDS-PAGE
-
Endotoxin-Niveau
- Endotoxin is < 1.0 EU/mg as determined by the LAL method
-
Immunogen
- The epidermal growth factor receptor is the cell-surface receptor for members of the epidermal growth factor family (EGF-family) of extracellular protein ligands.
-
Isotyp
- IgG1 kappa
-
-
-
-
Applikationshinweise
- Optimal working dilution should be determined by the investigator.
-
Kommentare
-
NOT FOR THERAPEUTIC USE - This is a research-grade biosimilar.
-
Beschränkungen
- Nur für Forschungszwecke einsetzbar
-
-
-
Konzentration
- 1 mg/mL
-
Buffer
- PBS with 0.02 % Proclin 300.
-
Konservierungsmittel
- ProClin
-
Vorsichtsmaßnahmen
- This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
-
Lagerung
- 4 °C,-20 °C
-
Informationen zur Lagerung
- Store at 4°C for up to 3 months. For longer storage, aliquot and store at -20°C.
-
-
- EGFR (Cetuximab Biosimilar)
-
Substanzklasse
- Biosimilar
-
Hintergrund
- EGFR, ErbB-1, HER1, epidermal growth factor receptor
-
UniProt
- P00533
Target
-